Abstract
Background
Advanced liver fibrosis and cirrhosis represent independent risk factors for hepatocellular carcinoma (HCC). There is also evidence suggesting that several etiologies of chronic liver disease elevate the risk for non-hepatic cancers, including nonalcoholic fatty liver disease (NAFLD), alcohol abuse, and hepatitis C infection. In the present study, we aim to characterize the cancer incidence in patients with chronic liver disease and assess the prognostic value of non-hepatic cancer on the decompensation events of this population.
Methods
We retrospectively reviewed the electronic medical records of patients who underwent transient elastography (TE) of liver, at John H. Stroger Hospital in Cook County, Chicago, IL. We identified patients who had decompensation of cirrhosis. We also extracted their cancer history. The cancer profiles of the cohort were compared by the presence or absence of advanced liver fibrosis. We then performed univariate and multivariate forward stepwise Cox regression analysis to identify the significant risk factors for the decompensation events and plotted Kaplan-Meier curve to demonstrate the significance of cancer in the prediction of decompensation events.
Results
We identified a total of 3097 patients who underwent TE. A total of 45 liver decompensation events were documented. In the univariate Cox regression model, MELD-Na score (hazard ratio (HR) 1.25, p < 0.001), liver stiffness measurement (HR 1.05, p = 0.004), and history of any cancer (HR 3.81, p = 0.001) emerged as predictors of decompensation. Non-hepatic cancer proved to be a significant predictor of decompensation (HR 3.57, p = 0.002).
Conclusion
The present study represents the first attempt to the best of our knowledge to describe the cancer incidence in this high-risk population. We found that non-HCC cancers independently predict hepatic decompensation events, which is an intriguing finding. We propose that physicians should be more vigilant to cancer history of patients with chronic liver disease as it might provide valuable prognostic information and guide individualized treatment and surveillance plans.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sanna C, Rosso C, Marietti M, Bugianesi E. Non-alcoholic fatty liver disease and extra-hepatic cancers. Int J Mol Sci. 2016;17(5):E717. https://doi.org/10.3390/ijms17050717 Review. PubMed PMID: 27187365; PubMed Central PMCID: PMC4881539.
Sørensen HT, Mellemkjaer L, Jepsen P, Thulstrup AM, Baron J, Olsen JH, et al. Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study. J Clin Gastroenterol. 2003;36:356–9.
Kalaitzakis E, Gunnarsdottir SA, Josefsson A, Björnsson E. Increased risk for malignant neoplasms among patients with cirrhosis[J]. Clin Gastroenterol Hepatol. 2011;9(2):168–74.
Nyberg AH, Sadikova E, Cheetham C, et al. Increased cancer rates in patients with chronic hepatitis C[J]. Liver Int. 2019.
Boffetta P, Hashibe M. Alcohol and cancer[J]. Lancet Oncol. 2006;7(2):149–56.
Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–50.
Singh S, Fujii LL, Murad MH, Wang Z, Asrani SK, Ehman RL, et al. Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11(12):1573–84.e1–2. https://doi.org/10.1016/j.cgh.2013.07.034 quiz e88–9Review. PubMed PMID: 23954643; PubMed Central PMCID: PMC3900882.
Sporea I, Raţiu I, Sirli R, Popescu A, Bota S. Value of transient elastography for the prediction of variceal bleeding. World J Gastroenterol. 2011;17(17):2206–10. https://doi.org/10.3748/wjg.v17.i17.2206 PubMed PMID: 21633530; PubMed Central PMCID: PMC3092872.
Usami M, Miyoshi M, Yamashita H. Gut microbiota and host metabolism in liver cirrhosis. World J Gastroenterol. 2015;21(41):11597–608. https://doi.org/10.3748/wjg.v21.i41.11597 Review. PubMed PMID: 26556989; PubMed Central PMCID: PMC4631963.
Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112(3):580–93. https://doi.org/10.1038/bjc.2014.579 PubMed PMID: 25422909; PubMed Central PMCID: PMC4453639.
Lv YF, Chang X, Hua RX, Yan GN, Meng G, Liao XY, et al. The risk of new-onset cancer associated with HFE C282Y and H63D mutations: evidence from 87,028 participants. J Cell Mol Med. 2016;20(7):1219–33. https://doi.org/10.1111/jcmm.12764 PubMed PMID: 26893171; PubMed Central PMCID: PMC4929296.
Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol. 2004;40(6):897–903.
Khan R, Ravi S, Chirapongsathorn S, Jennings W, Salameh H, Russ K, et al. Model for end-stage liver disease score predicts development of first episode of spontaneous bacterial peritonitis in patients with cirrhosis. Mayo Clin Proc. 2019;94(9):1799–806. https://doi.org/10.1016/j.mayocp.2019.02.027.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Wang, Y., Attar, B.M., Agrawal, R. et al. Non-hepatic Cancers Independently Predict Liver Decompensation Events. J Gastrointest Canc 52, 523–528 (2021). https://doi.org/10.1007/s12029-020-00409-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12029-020-00409-9